SCHEMBL384815

SCHEMBL384815

COc1cccc2c1C(=O)NC2=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 1/20 0.55
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
CASP3 P42574 1/20 0.52
KCNA5 P22460 1/20 0.51
STK10 O94804 6/20 0.50
SLK Q9H2G2 6/20 0.50
GSK3B P49841 5/20 0.50
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 2/20 0.50
CLK2 P49760 1/20 0.50
GSK3A P49840 1/20 0.50
STK33 Q9BYT3 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
TLK1 Q9UKI8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29378366 1.00 TOP1 (0.55) TOP1CA1CA2CA7CA9
SCHEMBL9768590 0.85 KDM4E (0.51) TOP1CA1CA2CA7CA9
SCHEMBL262473 0.84 GSK3B (0.50) CASP3KCNA5STK10SLKGSK3B
SCHEMBL28099802 0.84 GSK3B (0.50) CASP3KCNA5STK10SLKGSK3B
SCHEMBL1477960 0.84 CA1 (0.50) TOP1CA1CA2CA7CA9
SCHEMBL27447700 0.81 STK10 (0.64) CASP3STK10SLKGSK3BALDH1A1
SCHEMBL7399139 0.80 DDB1 (0.46) CASP3GSK3BALDH1A1MEN1KMT2A
SCHEMBL4869329 0.80 CA1 (0.58) CA1CA2CA7CA9CASP3
SCHEMBL28678417 0.80 PARP1 (0.58) TOP1CA1CA2CA7CA9
SCHEMBL7964993 0.79 CA1 (0.56) CA1CA2CA7CA9STK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4206205-B1 PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND PRIMEGENE BEIJING CO LTD (CN) 2026-03-04 EP claimed
CN-119662034-A High-modulus impact-resistant modified asphalt, asphalt mixture, and preparation method and application thereof 廊坊京台高速公路有限公司 2025-03-21 CN claimed
US-20230303578-A1 PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND PRIMEGENE (BEIJING) CO., LTD. (CN) 2023-09-28 US claimed
EP-4206205-A1 PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND Primegene (Beijing) Co., Ltd. (CN) 2023-07-05 EP claimed
WO-2022042577-A1 PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND 北京普祺医药科技有限公司 2022-03-03 WO claimed
US-20050137391-A1 Process for the synthesis of oligomeric compounds IONIS PHARMACEUTICALS, INC. 2005-06-23 US claimed
EP-4206205-B1 PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND PRIMEGENE BEIJING CO LTD (CN) 2026-03-04 EP disclosed
CN-119662034-A High-modulus impact-resistant modified asphalt, asphalt mixture, and preparation method and application thereof 廊坊京台高速公路有限公司 2025-03-21 CN disclosed
CN-119662034-A High-modulus impact-resistant modified asphalt, asphalt mixture, and preparation method and application thereof 廊坊京台高速公路有限公司 2025-03-21 CN disclosed
US-20230303578-A1 PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND PRIMEGENE (BEIJING) CO., LTD. (CN) 2023-09-28 US disclosed
EP-4206205-A1 PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND Primegene (Beijing) Co., Ltd. (CN) 2023-07-05 EP disclosed
WO-2022042577-A1 PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND 北京普祺医药科技有限公司 2022-03-03 WO disclosed
US-9914719-B2 Hydroxybenzamide derivatives and their use as inhibitors of HSP90 ASTEX THERAPEUTICS LTD. (GB) 2018-03-13 US disclosed
US-20070259886-A1 (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma ASTEX THERAPEUTICS, LTD. (GB) 2007-11-08 US disclosed
WO-2006109085-A1 HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 ASTEX THERAPEUTICS LIMITED (GB) 2006-10-19 WO disclosed
US-4556651-A Secalonic acid derivatives as antitumor agents ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1985-12-03 US disclosed
EP-0064199-B1 NOVEL SECALONIC ACID DERIVATIVES AND METHOD FOR PREPARING THEREOF Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1985-08-21 EP disclosed
US-4418061-A ANTITUMOR AGENTS ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1983-11-29 US disclosed
EP-0064199-A1 Novel secalonic acid derivatives and method for preparing thereof Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1982-11-10 EP disclosed
US-4144072-A CONTAINING A PHTHALAZINONE AND A PHTHALIMIDE FUJI PHOTO FILM CO., LTD. (JP) 1979-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259886-A1 (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma HSP90AB2P, HSP90AA1, HSP90AB1 TOP1 2091/4885CA1 4633/4885CA2 4713/4885
US-20050137391-A1 Process for the synthesis of oligomeric compounds PFAS, DIS3, EXOSC4 TOP1 2412/4885CA1 4437/4885CA2 4523/4885
US-20230303578-A1 PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND DPYD, RPLP2, DHPS TOP1 1163/4885CA1 4373/4885CA2 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.